IQVIA and Waters: Two Stocks for the AI Revolution in the Biotech Lab - Now Facing New Trend-Following Signals
Reading Time: 3 minutes
The AI revolution is increasingly reaching real drug development. Not only active ingredients are being searched with AI. Laboratories, clinical trials, and the evaluation of biological data are also being automated and accelerated. With IQVIA and Waters, two beneficiaries of this development are technically poised for new trend-following signals. Their business models target different points in the same value chain. IQVIA: Conducting the Clinical Trial Before the Clinical Trial with AI IQVIA is increasingly evolving into the data and AI infrastructure...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
